Table 1.
Baseline patient and tumour characteristics.
| US at week 6, N = 340 | US at surgery, N = 309 | MMG at week 6, N = 267 | MMG at surgery, N = 248 | |
|---|---|---|---|---|
| Age (years) | N (%) | |||
| <65 | 300 (88.24) | 271 (87.70) | 237 (88.76) | 219 (88.31) |
| ≥65 | 40 (11.76) | 38 (12.30) | 30 (11.24) | 29 (11.69) |
| Treatment | N (%) | |||
| Lap | 119 (35.00) | 108 (34.95) | 94 (35.21) | 84 (33.87) |
| Trast | 107 (31.47) | 100 (32.36) | 82 (30.71) | 79 (31.85) |
| Lap + Trast | 114 (33.53) | 101 (32.69) | 91 (34.08) | 85 (34.27) |
| HR status | N (%) | |||
| Positive | 171 (50.29) | 157 (50.81) | 133 (49.81) | 121 (48.79) |
| Negative | 169 (49.71) | 152 (49.19) | 134 (50.19) | 127 (51.21) |
| cN | N (%) | |||
| N0/1 | 287 (84.41) | 265 (85.76) | 216 (80.90) | 206 (83.06) |
| N ≥ 2/X/missing | 53 (15.59) | 44 (14.24) | 51 (19.10) | 42 (16.94) |
| cT | N (%) | |||
| T2 | 214 (62.94) | 193 (62.46) | 152 (56.93) | 142 (57.26) |
| T = 3 | 126 (37.06) | 116 (37.54) | 115 (43.07) | 106 (42.74) |
| Planned surgery | N (%) | |||
| Mastectomy | 245 (72.06) | 210 (67.96) | 200 (74.91) | 176 (70.97) |
| BCS | 95 (27.94) | 99 (32.04) | 67 (25.09) | 72 (29.03) |
Abbreviations: cN: clinical nodal status; cT: clinical tumour size; HR: hormone receptors; Lap: lapatinib; Lap + Tras: lapatinib + trastuzumab; Tras: trastuzumab; MMG: mammography; BCS: breast-conserving surgery; US, ultrasound.